Skip to main content

Spero Therapeutics, Inc.

SPRO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001701108

No open-market purchases or sales by Spero Therapeutics, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $47.5M in total; no superinvestor holds it.

Q4 2021 vs. Q3 2021

How the institutions holding Spero Therapeutics, Inc. changed between Q3 2021 and Q4 2021.

All holders in Q4 2021All holders in Q3 2021

13F holders of SPRO: Q3 2021 compared with Q4 2021
MeasureQ3 2021Q4 2021Change
Holders8884−4
Shares18.4M19.8M+1.42M (+7.7%)
Value$338.3M$316.7M−$21.7M (−6.4%)

New holders (9)

Institutions that held Spero Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.

Institutions new to SPRO in Q4 2021
InstitutionSharesValue% of portfolio
Atlas Venture Life Science Advisors, LLC1,031,160$16.5M1.52%
OUP Management Co., LLC249,070$3.99M1.80%
State of Wisconsin Investment Board31,600$506.0K0.00%
Allspring Global Investments Holdings, LLC10,186$163.0K0.00%
TD Waterhouse Canada Inc.500$7.45K0.00%
Steward Financial Group LLC354$5.00K0.00%
Beaird Harris Wealth Management, LLC282$5.00K0.00%
PFS Partners, LLC250$4.00K0.00%
CoreCap Advisors, LLC142$2.00K0.00%

Sold out (13)

Institutions that held Spero Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.